Live Breaking News & Updates on Ulcerative Colitis Expected

Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar. ....

United States , Carl Spana , Exchange Commission , Palatin Technologies Inc , Prnewswire Palatin Technologies Inc , Securities Exchange , Association For Research , Colitis Congress , Patient Enrollment , Dry Eye Disease , Private Placement , Convertible Redeemable Preferred Stock , Ulcerative Colitis Expected , Start Next Month , Quarter Ended Fiscal Year , Hypoactive Sexual Desire Disorder , Key Opinion Leader , Seriesb Convertible Redeemable Preferred Stock , Seriesc Convertible Redeemable Preferred Stock , Seriesb Preferred Stock , Seriesc Preferred Stock , United States Securities , Fiscal Quarter Ended March , Termination Agreement , Preferred Stock , Melanocortin Receptor Agonists ,